Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Apr 05, 2021 1:25pm
67 Views
Post# 32937769

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Cytodyn -financing

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Cytodyn -financingAs per website they are still at preclinical stage in cancer program and the trial is expected to begin in q2?
The website and news section is the main source of information for THTX, the idea is to make it easy for interested folks to get a decent understanding of where the company is in terms of their business not conflicting messages!! Again how hard is it to correct that for a company which is supposed to be a " growing their business to become a significant player in the pharma industry"? Some say website is not important, we need hard data, results will sell themselves etc...
I believe a low valuation should be addressed by the company at at any given time until the issue is resolved. I don't look for excuses why they are undervalued but for reasons.
<< Previous
Bullboard Posts
Next >>